Dendreon gets $130M facility

DNDN entered into a financing agreement with Azimuth Opportunity in which the cancer company may sell Azimuth up to $130 million of stock over the next 18 months at a discount to market. The shares will be sold from an existing shelf registration, with Reedland Capital Partners acting as placement agent. At June 30, DNDN had $135 million in cash and a six-month operating loss of $54.8 million. Azimuth is advised by Acqua Capital. ...